Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
about
Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3+ T cells in canine B cell lymphoma.DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in miceCuring mice with large tumors by locally delivering combinations of immunomodulatory antibodies.Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistanceSignificant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine.Dose-dense chemotherapy improves mechanisms of antitumor immune response.Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammationCurrent status and future applications of cellular therapies for cancer.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Immunological dysregulation in multiple myeloma microenvironment.Adapting conventional cancer treatment for immunotherapy.OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.The renaissance of anti-neoplastic immunity from tumor cell demise.Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma.T cell modulation by cyclophosphamide for tumour therapy.
P2860
Q34041661-3CE2054F-4AB8-4A44-9FC9-C0A410457565Q34939255-CAA253E4-6584-4CAE-B578-1AA62804D934Q35107009-4291FC4A-73F3-4575-90C5-0070C114F3EDQ36125878-C613C046-2245-4C5E-A19A-071391ED3362Q36497647-2E540D65-1D6B-4090-A9B1-5E5DD0DF0CECQ36511042-FBC84C8C-63DD-48BB-A907-530B97DB4390Q36936462-7E288019-8EAA-4DB3-9C40-31C3BA0CF46FQ37861216-8EAAB0E4-9E8E-42A2-91A0-24E7B394D225Q38115968-6487B2C4-8D05-4A7C-8D29-24DB85CD9790Q38161367-62DC359B-1B44-488C-A7A2-0740504127BFQ38228353-F2071B12-D190-4747-A0AD-BE29C8F86F26Q38748185-A845DFE9-2633-4146-95DC-9D3039DC45A5Q39866378-E78D9261-7825-4FD5-B787-0E7335F063DDQ41438622-FB0F4EFC-9698-4F9A-AF17-CDF3E13331E7Q48193643-DCACDE9E-53E7-4FD9-9ACD-A3CDCC563A17Q48633948-806E5170-53E7-49CC-B21B-500A5A74961EQ49822317-80CB856A-32C2-478B-BB4A-72EC005D4EFC
P2860
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
@ast
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
@en
type
label
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
@ast
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
@en
prefLabel
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
@ast
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
@en
P2093
P2860
P1476
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
@en
P2093
Ingegerd Hellstrom
Jade Jaffar
Karl Erik Hellstrom
P2860
P356
10.1097/CJI.0B013E3181B56AF4
P577
2010-01-01T00:00:00Z